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What is already known about this subject  
- Approximately 80% of people with T2DM are overweight or obese  
- Weight loss produces numerous benefits in T2DM 
- People with T2DM have difficulty losing and maintaining weight 
 
What this study adds  
- Provision of a VLCD with group support and behaviour therapy for patients with 
T2DM is feasible within a community-based setting with trained facilitators 
- VLCD approaches for weight management in T2DM can achieve more than 90% of 
weight loss as compared to obese individuals without T2DM  
- Identification of the need to investigate the full impact of this approach in patients with T2DM 
by assessing changes in glycaemia, liver function and medication. 
 
 
 
Abstract 
 
Approximately 80% of people with type 2 diabetes mellitus (T2DM) are overweight or obese, and 
obesity compounds the cardiovascular risk of T2DM. The aim of this retrospective study was twofold: 
first to investigate whether a 12 week, community based VLCD programme can result in important 
weight loss; and second to investigate any potential difference in the weight loss achieved using this 
community based approach in individuals with and without T2DM. Three hundred and fifty five 
participants with T2DM were matched for age, BMI and gender to participants without T2DM (Total 
cohort comprised 204 males: 506 females; (mean ± standard deviation) age (years) 54.0 ± 9.1; BMI 
(kg/m2) 41.6 ± 8.1; weight (kg) 116.1 ± 25.1).  The programme included a daily intake of 550kcal in 
addition to group support and behaviour therapy provided by trained facilitators within a community-
based setting. After 12 weeks, there was significant weight loss within each group when compared to 
baseline (T2DM: 115.0 ± 24.4 kg vs 96.7 ± 21.4 kg, p <0.0001; non-T2DM:  117.2 ± 25.8 kg vs 97.3 ± 
22.2 kg, p < 0.0001).  At 12 weeks, weight change (-18.3 ± 7.3 kg vs -19.9 ± 7.0 kg, p = 0.012) and 
BMI change (-6.7 ± 2.9 kg/m2 vs -7.1 ± 2.1 kg/m2, p = 0.011) were significantly less in the T2DM 
group when compared to the non-T2DM group. Our results suggest that the use of VLCD approaches 
for weight management in T2DM can achieve more than 90% of the weight loss seen in obese 
individuals without T2DM. 
 
 
 
Introduction 
 
Among those individuals with type 2 diabetes mellitus (T2DM) approximately 80% are overweight or 
obese (1). Obesity compounds the cardiovascular risk of T2DM, such that T2DM individuals 20–30% 
above their ideal body weight have a 2.5–3 fold increase in premature mortality compared to people 
with diabetes who have a healthy body weight. Premature mortality rises to greater than a fivefold 
increased risk for individuals >40% above their healthy weight (2). Furthermore, obesity complicates 
the management of T2DM, increasing insulin resistance and glucose intolerance, making diabetes in 
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the obese population difficult to treat pharmacologically and also increases the likelihood of 
individuals with diabetes developing hypertension and cardiovascular complications (3-8). 
 
The financial cost of diabetes in the UK has been estimated to be 10% of the NHS budget (9) and 7% 
of all prescription costs per year (10), thus making the treatment of obesity and diabetes of primary 
concern. Weight loss produces numerous benefits in T2DM including improved glucose metabolism; 
reduction in glycated haemoglobin, fasting insulin levels and increased insulin sensitivity; reduction in 
blood pressure; and improvements in lipid profile with decreased triacylglycerols, increased high 
density lipoprotein cholesterol (HDL-C) and reduced low density lipoprotein cholesterol (LDL-C) 
(11,12). Due to the well documented association between obesity and increased health risks, utilising 
weight-loss as an effective strategy is a recommendation by public health authorities and many 
physicians (12). Studies assessing the effects of weight loss medication such as fenfluramine and 
phentermine (13), orlistat (14) and sibutramine (15), have demonstrated the relatively small, but 
clinically significant weight loss which resulted in improvements in HbA1c, although only a moderate 
improvement was observed with the use of sibutramine.  Studies on the use of different dietary 
approaches have yielded mixed results. For example, the use of a combination of weight loss 
therapies (including meal replacements, low calorie diet and sibutramine) resulted in a 4.6kg weight 
loss and decrease in HbA1c of 0.5% at 2 years (16), whereas in the study by Milne et al (17) three sets 
of dietary guidelines for type 2 diabetes were compared (a weight-management diet, a high-
carbohydrate/fibre diet, or a modified-lipid diet) and no significant changes in body weight were 
observed  at 18 months. Distchuneit et al (18), reported a weight loss of 11.3% of starting weight at 27 
months by using meal replacements.  It appears that conventional methods of dietary treatment result 
in individuals with T2DM losing approximately 50% less weight then their non-T2DM counterparts 
(19,20), confirming the original observations of Wing et al (21) in a 20-week behavioural weight control 
program consisting of self monitoring, stimulus control, cognitive restructuring and contingency 
contracting.  
 
Nevertheless, dietary modification remains the first line treatment in the management of obese people 
with T2DM (22) and patients with type 2 diabetes do show improvements in weight, fasting glucose, 
HbA1c, insulin sensitivity and blood pressure following the use of a very low calorie diet (VLCD) 
(23,24). Although these diets have been associated with side effects such as nausea, halitosis, 
constipation and transient hair loss (25),  Dhindsa et al (23) have suggested giving greater 
consideration in the use of VLCDs (<800 kcal/day) in the treatment of the ‘difficult-to-manage and 
symptomatic patient group’. This is supported by a recent systematic review which suggested the 
need for further standardised research of VLCD use in obese but otherwise healthy, and at risk 
groups, the results of which could better inform best practice (26).  
 
We hypothesise that the use of a VLCD in combination with behaviour therapy could result in 
important weight loss in patients with and without T2DM. The aim of this retrospective study was 
twofold: first to investigate whether a 12 week, community based VLCD programme can result in 
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important weight loss; and second to investigate any potential difference in the weight loss achieved 
using this community based approach in individuals with and without T2DM.  
 
Materials and Methods  
 
Source of Data 
For this retrospective analysis, data were included from participants with complete data at baseline 
and 12 weeks and who were recruited onto the weight loss programme between 2007 and 2010. 
Ethical permission for this analysis was obtained from the Robert Gordon University Ethics 
Committee. 
 
Study Population 
Participants were self-referred, and prior to starting the programme, their fitness to participate was 
assessed by their GP using a standardised form provided by LighterLife which assesses health 
status. Potential clients were included if they met the requirements above or were  excluded from 
taking part in the LighterLife Total programme if the met any of the following criteria: type 1 diabetes; 
porphyria; total lactose intolerance; major cardiovascular or cerebrovascular disease; history of renal 
disorder or hepatic disease; active cancer; epilepsy, seizures, convulsions, major depressive disorder, 
psychotic episodes, schizophrenia, bipolar disorders, delusional disorders; current suffering from 
anorexia, bulimia or undergoing treatment for any other eating disorder; are pregnant or 
breastfeeding; have given birth or had a miscarriage in the last 3 months. 
 
Participants with T2DM (n=355) were then matched for age, BMI and gender to participants without 
T2DM (n=355).  The groups were first matched within the tolerance of ±1 BMI unit and an exact 
match for age and gender (n = 284 individuals). For those individuals in the T2DM group who did not 
have a corresponding match, the BMI tolerance was increased up to ±2 BMI units and an exact match 
for age and gender were obtained (n=71 individuals). Baseline demographics and 12 week changes 
in weight were compared for the two groups. 
 
Weight loss programme 
For those individuals who were eligible, the intervention was carried out within a community based 
setting and not in a specialist unit.  Appointments and treatments were managed by lay, but trained 
behaviour change facilitators.   Requirement for drug change was determined by the participant’s GP 
or diabetic specialist nurses. Where required, patients’ insulin doses were halved and sulfonylureas 
were stopped prior to the commencement of the diet.  Participants attended their GP/diabetic 
specialist nurse at least monthly for ongoing review of medication requirements whilst losing weight.   
 
The intervention used was a commercial weight-management programme (LighterLife Total). This is a 
tripartite approach for individuals with BMI≥30 kg/m2 comprising of a VLCD and group support, along 
with behaviour therapy. The programme aims to achieve weight loss and to identify personal 
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psychological motivation for over-consumption, thereby enabling participants to develop robust 
strategies for more successful weight management in the future. 
 
Diet and nutrition 
The VLCD provides a daily intake of 550kcal (50g protein, 50g carbohydrate, mean 17g fats i.e. 36% 
Energy from protein, 36% carbohydrate and 28% fat) in the form of food packs (soups, shakes, 
textured meals and bars) which contain ≥100% recommended daily allowances (RDA) for vitamins 
and minerals including Vitamins A, C, D, E, K, thiamine, riboflavin, niacin, B6, B12, folic acid, biotin, 
and  pantothenic acid, calcium, phosphorous, iron, zinc, magnesium, iodine, potassium, sodium, 
copper, manganese, selenium, molybdenum, chromium, chloride, fluoride ). Clients were also able to 
purchase an ancillary “fibre mix” to add to their water which contains inulin as the source of fibre. 
 
Participants undertook the VLCD alongside a unique behaviour-change programme developed 
specifically for weight management in the obese. This is informed by concepts from cognitive 
behavioural therapy and transactional analysis (transactional cognitive behavioural therapy – TCBT®) 
and addiction/change theory (27-30). It is delivered in small, single-sex, weekly groups by weight-
management counsellors who are specifically trained in the facilitation of behaviour change for the 
treatment of obesity. 
 
 Measurements 
Measurements of height and weight took place in LighterLife centres and were carried out by the 
facilitators who have been trained and provided with protocols developed within LighterLife.  The 
actual types of equipment used for these measurements was not recorded.  Measurements were 
taken during weekly meetings which occurred at the same location and time each week.  
 
Statistical Analysis 
All variables were assessed for normality. The only variables normally distributed were waist 
circumference at baseline and waist circumference at 12 weeks. All of the other variables required the 
use of non-parametric tests. Baseline comparisons were carried out by independent t-test or Mann-
Whitney U test for continuous data and by Chi square for categorical data. Paired t-tests or Wilcoxon 
matched pairs test were carried out to assess within group changes. Comparison of rate of weight 
loss between the two groups was also assessed using the Mann-Whitney U test.  A sensitivity 
analysis was performed by removing participants who were not matched exactly for gender, age and 
+/-1 BMI unit (n =71). In addition, a sub-analysis was carried on Caucasian subjects alone in order to 
avoid any effects due to ethnicity.  Data were analysed using SPSS for Windows (version 17.0) 
(SPSS Inc., Chicago, IL, USA) 
 
Power 
The sample size  (355 per group) for this retrospective analysis provided a power greater than 80% to 
detect a minimum difference in weight change between the two groups of 1.69kg.  
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Results 
A total of 1246 individuals with T2DM undertook the LighterLife Total VLCD programme from 2007-
2010. Of these, 698 followed the diet for at least 12 weeks, 355 (102 men, 253 women) of which we 
were able to match adequately for gender, age and BMI against a group of men and women without 
T2DM. Mean age, BMI, weight, height and ethnicity are described in Table 1 (mean ± standard 
deviation). As a result of the matching there were no significant differences between the participants 
with and without T2DM at baseline (Table 1).  
 
After 12 weeks on the VLCD, there was significant loss of weight within each group when compared 
with baseline (T2DM group 115.0 ± 24.4 kg vs 96.7 ± 21.4 kg, p <0.0001; non-T2DM group 117.2 ± 
25.8 kg vs 97.3 ± 22.2 kg, p < 0.0001).  There was a significant difference in weight change (-18.3 ± 
7.3 kg vs -19.9 ± 7.0 kg, p = 0.012) and BMI change (-6.7 ± 2.9 kg/m2 vs -7.1 ± 2.1 kg/m2, p = 0.011) 
at 12 weeks between the two groups. Similarly, percent weight loss was significantly greater in the 
non-T2DM group when compared to the T2DM at 12 weeks (17.1 ± 4.4% vs 15.5 ± 10.0%, p = 0.006).  
 
There were significant differences in the rate of weight loss between the two groups at certain time 
points, and overall as shown in Figure 1. Greatest weight loss was achieved after the first week of 
weight loss where individuals with T2DM lost 4.3 ± 8.2 kg and the non-T2DM lost 3.8 ± 2.3 kg. The 
least amount of weight loss achieved was in the last week of weight loss where individuals with T2DM 
lost 0.6 ± 4.9 kg and the non-T2DM lost 0.9 ± 1.7 kg. There was no significant difference in weight 
loss between the two groups for the first 3 weeks. From week 4 to week 12, weight loss was 
significantly less in the T2DM group than the non-T2DM group (P values were 0.036, 0.022, 0.015, 
0.016, 0.007, 0.015, 0.010, <0.0001 for weeks 4-12 respectively). Average rate of weight loss was 
significantly slower in the T2DM group than in the non-T2DM group (-1.27 ± 0.9 kg/week vs -1.47 ± 
0.6 kg/week, p = 0.005). Interestingly, the difference in weight loss at 12 weeks was reduced slightly 
when non-Caucasians were removed from the analysis (from 1.6 to 0.4kg) and was no longer 
significant between the two groups (T2DM group -18.5 ± 7.4) kg vs non-T2DM group -19.9 ± 7.1 kg; p 
= 0.075).  
 
A secondary analysis was carried out by comparing the outcomes by gender (Table 2). In both the 
T2DM and non T2DM groups, men were taller and heavier than their female counterpart but BMI was 
not significantly different. Weight change at 12 weeks was significantly greater in males than in 
females for both the T2DM and non-T2DM groups. Percent weight change at 12 weeks was not 
significantly different between men and women in the T2DM group, but was significantly different in 
the non-T2DM group (p = 0.009).  
 
When females in the T2DM group were compared to females in the non-T2DM, there were no 
differences in baseline variables, absolute or percentage weight change at 12 weeks (Table 2). 
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When males in the T2DM group were compared to males in the non-T2DM group, no significant 
differences were observed at baseline. However, absolute and percentage weight change were 
significantly greater in the non-T2DM group at 12 weeks (Table 2). 
 
Sensitivity analysis 
Following a sensitivity analysis, where individuals were matched exactly for gender, age and within ± 
1 BMI unit, there were no significant differences in changes in weight between patients with and 
without T2DM. Percent weight change at 12 weeks, however, remained significantly greater in the 
non-T2DM (T2DM 15.7 ± 10.8 % vs non-T2DM 17.0 ± 4.6 %, p= 0.045). There were no differences 
between T2DM and non-T2DM in either absolute weight change or % change in the individual gender 
groups’ 
 
 
Discussion 
 
Previous observations in individuals with T2DM demonstrated that the weight loss achieved was 
approximately 50% less than seen in the non-diabetic patient (14,19,21,31-34) when the best diet and 
lifestyle advice and support is given, either with or without anti-obesity drug therapy. However, there is 
emerging evidence that individuals with T2DM can achieve similar weight loss to their non-T2DM 
counterparts (35,36). Our findings are of particular interest because, although this was a retrospective 
analysis, the results demonstrate that a community based VLCD programme, carried out by trained 
facilitators, can result in important weight loss. In addition, although we observed a significant 
difference in weight loss between individuals with and without T2DM, this was an average difference 
of 1.6 kg which was less than 10% of the non-T2DM weight loss, compared to the previously reported 
differences of 50%.  This emphasises the applicability of this weight loss programme for individuals 
with T2DM. 
 
Our findings also suggest that there may be a gender influence on the rate of weight change seen in 
people with T2DM. While women with and without T2DM showed a similar absolute and percentage 
weight loss over the 12 weeks, men with T2DM had significantly smaller absolute and percentage 
weight losses than men without T2DM. This difference in gender response to weight loss for patients 
with and without T2DM has not been reported before. This could be due to a different sample sizes 
between the two groups; however there may also be differences in medication use or duration of 
T2DM which we are unable to correct for. Nevertheless, this difference would be interesting to 
investigate in future studies. Our results also suggested that there is an ethnic difference in the rate of 
weight loss. Unfortunately, the numbers for non-Caucasian ethnic groups were limited here and we 
were unable to assess the impact of ethnicity to its full extent. 
 
Our sensitivity analysis demonstrated that there no longer was a difference in absolute and 
percentage weight loss between individuals with and without T2DM.  However, the interpretation of 
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this sensitivity analysis remains limited due to the reduced power and results should be confirmed in 
future studies with larger sample size 
 
The weight loss observed in our study was much greater (and more rapid) than observed in previous 
dietary (36-38) and drug studies (15,39) in patients with T2DM. This is important as recent evidence 
clearly demonstrates the implications of weight loss in terms of possible benefits to insulin sensitivity. 
Lim et al (40) demonstrated that following a VLCD, the resulting acute negative energy balance 
reverses T2DM by normalising both hepatic insulin sensitivity and beta cell function through the 
reduction of fat in the liver and pancreas.  This is in line with our previous findings which 
demonstrated improvements in liver enzymes following a VLCD (25). It seems likely that these 
improvements would occur earlier with a VLCD, where rapid weight loss is achieved, as compared to 
gradual weight loss, but this remains to be determined. In addition, Anderson et al (41) also 
demonstrated that after twelve weeks of an energy-restricted diet, significant improvements in fasting 
plasma glucose, serum cholesterol, serum triacylglycerols, systolic blood pressure, and diastolic 
blood pressure were observed. They also commented that larger weight losses were associated with 
larger reductions in these values (41), and greater weight loss maintenance (42).  
 
It was interesting to observe that the T2DM lost weight more rapidly during the first 2-3 weeks and 
then slowed down compared to non-T2DM group. A similar observation was made by Baker et al (35) 
who suggested that this may have been in relation to reversal of sodium retention associated with 
hyperinsulinemia, or greater reductions in glycogen storage. 
 
One of the main limitations of this study was the lack of information on medication as well as changes 
in glycaemia and insulin sensitivity. Information about these two aspects would have shed more light 
on the effects of acute weight loss on the potential reversal of the disease. Nevertheless, as 
mentioned above, there is evidence in the literature to support such beneficial effects. The lack of 
information on medications is also of importance in terms of ability to lose weight. Although insulin 
dose is halved prior to engaging on the VLCD, some patients may have remained on insulin which 
would have limited the magnitude of the weight loss. Also, there was no information available on 
frequency of hypoglycaemia, the treatment of which would be expected to attenuate weight loss in 
these individuals. 
 
In addition, glucose tolerance status for the individuals included in the matched non-diabetic group 
was not verified. This may have resulted in the inclusion of individuals with undiagnosed type 2 
diabetes in the non-diabetic group which in turn may have diminished the difference between the two 
groups.  
 
Another limitation of this study was the lack of assessment of changes in physical activity, and this 
should be addressed in future research. Nevertheless, given the average BMIs of both groups was 
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greater than 40kg/m2, it is unlikely that individuals in this study were able to undertake the regular 
exercise required to achieve weight loss (43).  
 
Finally, we are aware that there may be bias introduced by the selection of individuals who completed 
twelve weeks of weight loss, which therefore renders an intention to treat analysis impossible. 
However, this does assess the actual efficacy of the intervention when individuals are able adhere to 
it.  
 
Conclusion 
Unlike standard dietary, lifestyle and pharmacological approaches, the use of VLCD approaches for 
weight management in T2DM can achieve more than 90% of the weight loss seen in obese 
individuals without T2DM. The amount of weight lost (>15% of start weight) is known to be associated 
with the reversal of the diabetic state to either impaired fasting glycaemia or normal glucose 
metabolism. VLCD therapy therefore offers approaches to dealing with T2DM and could be used as 
part of therapy in obese T2DM.  
 
Conflicts of interest 
CR has received lecture honoraria and has attended national/international meetings as a guest of 
LighterLife Ltd, UK. 
CR, IB have been involved with other companies with an interest in obesity.   
IB, KLJ, CJ, SL and LD are employed by LighterLife Ltd, UK. IM was an adviser to LighterLife Ltd, UK 
Acknowledgements 
Funding for this study was provided by LighterLife Ltd, UK.  
CR and IB designed the study. Data were collected by SL, CJ, LD. Data analysis and writing of 
manuscript were carried out by CR. CR, IB, IM and KLJ interpreted the data and commented on drafts 
of the manuscript. All authors had final approval of the submitted and published versions. 
 
References 
 
 
1. National Institutes of Health: Consensus Development Conference on diet and exercise in non-
insulin-dependent diabetes mellitus. Diabetes Care 1987; 10:639-644. 
 
2. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32:  
805–822. 
 
3. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. 
Diabetes Care 1997;20:1744-1766.  
 
4. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America, 2nd Ed. 
NIH Publication 95-1468. Bethesda, Md: National Institutes of Health, 1995. 
 
 
   
Page | 10 
 
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart  disease in 
subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial 
infarction. N Engl J Med 1998; 339:229-234.  
 
6. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. Journal 
of the Am Med Assoc 1999; 281:1291-1297.  
 
7. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction 
and mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339:861-867. 
 
8. Derby CA, Lapane KL, Feldman HA, Carleton RA. Sex-specific trends in validated  coronary heart 
disease rates in Southeastern New England, 1980-1991. Am J Epidemiol 2000;151:417-429. 
 
9. Department of Health (2006). Turning the corner improving diabetes care (web site accessed 21st 
May 2012, website address: www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications 
PolicyAndGuidance/DH_4136141) 
 
10. Yorkshire and Humber Public Health Observatory (2007). Prescribing for diabetes in England: 
analysis of volume, expenditure and trends. 2007 (website accessed 5th of December 2012, 
website address: http://www.yhpho.org.uk/resource/view.aspx?RID=45983) 
 
11. Pi-Sunyer X, Blackburn G, Brancati FL, et al., Reduction in weight and cardiovascular disease risk 
factors in individuals with type diabetes: one-year results of the look AHEAD trial, Diabetes Care 
2007; 30: 1374–1383. 
 
12. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of 
Overweight and Obesity in Adults: The Evidence Report. NIH publication  No 98-4083,1998. 
 
13. Redmon  JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JP. Pharmacologic induction 
of weight loss to treat type 2 diabetes. Diabetes Care 1999; 22: 896-903. 
 
14. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with   
type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288–94 
 
15. Fujioka  K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz He, Weinstein SP. Weight loss 
with sibutramine improves glycemic control and other metabolic parameters in obese patients with 
type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-187. 
 
16. Redmon JB, Raatz k, reck, KP, Swanson, JE, Kwong CA, Fan, Q, Thomas W, Bantle JP. One-
year outcome of a combination of weight loss therapies for subjects with type 2 diaebtes. Diabetes 
Care 2003; 26; 2505-2511. 
 
17. Milne RM, Mann JL, Chisholm, AW, Williams SM. Long-term comparison of three dietary 
prescriptions in the treatment of NIDDM. Diabetes Care 1994; 17: 74-80 
 
18. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a 
long-term dietary intervention in obese patients. Am J Clin Nutr 1999; 69:198-204. 
 
19. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term outcomes of the 
treatments for obesity and implications for health improvement and the economic consequences 
for the National Health Service. HTA 2004; 8: 1-458. 
 
20. Franz MJ. The dilemma of weight loss in diabetes. Diabetes Spectrum 2007; 20: 133-136. 
 
21. Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their 
overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-6. 
 
22. NICE Clinical Guidelines 87 (March 2010), Type 2 diabetes: The management of type 2 diabetes 
(update). Clinical Guideline 66. London: NICE, 2008. http://guidance.nice.org.uk/CG66 
 
   
Page | 11 
 
23. Dhindsa P, Scott AR, Donnelly R. Metabolic and cardiovascular effects of very-low-calorie diet 
therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year. 
Diabetic Med 2003; 20: 319–24. 
 
24. Jazet IM, de Craen AJ, van Schie EM, Meinders AE. Sustained beneficial metabolic effects 18 
months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 
diabetes. Diabet Res Clin Pr 2007; 77: 70–6. 
 
25. Rolland C, Hession M, Murray S, Wise A, Broom J. Randomised clinical trial of standard treatment 
versus a low carbohydrate/high protein diet or the LighterLife Programme in the management of 
obesity.  Journal of Diabetes 2009; 1:207-217. 
 
26. Mulholland Y, Nicokavoura E, Broom J, Rolland C. Very-low calorie diets and morbidity: A 
systematic review of longer term evidence. Br J Nutr 2012; 108: 832–851. 
 
27. Buckroyd J, Rother S, Therapeutic groups for obese women: A group leader’s handbook, Wiley & 
Sons Ltd, Chichester, 2007. 
 
28. Chaston TB, Dixon JB, Factors associated with percent change in visceral versus subcutaneous 
abdominal fat during weight loss: findings from a systematic review, Int J Obesity 2008; 32: 619-
628. 
 
29. Cooper Z, Fairburn CG, Hawker D, Cognitive Behavioral Treatment of Obesity: A clinician’s guide, 
Guildford Press, New York, 2003. 
 
30. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with 
lifestyle intervention or metformin, N Engl J Med 2002; 346: 393-403. 
 
 
31. Khan MA, St Peter JV, Breen GA, et al. Diabetes disease stage predicts weight loss outcomes 
with long-term appetite suppressants. Obes Res 2000; 8: 43-8. 
 
32. Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 
2 diabetes and poor blood glucose control. Diabetes Care 2001; 24:1957-60. 
 
33. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or 
obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72. 
 
34. Campos GM, Rabl C, Mulligan K, et al. Factors associated with weight loss after gastric bypass. 
Arch Surg 2008; 143: 877-83. 
 
35. Baker ST, Jerums G, Prendergast LA, Panagiotopoulos S, Strauss BJ, Proietto J. Less fat 
reduction per unit weight loss in type 2 diabetic compared with nondiabetic obese individuals 
completing a very-low-calorie diet program. Metab Clin Exper 2012; 61: 873-882.  
 
36. Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and 
long-term weight loss. Obes Res 1995; 3: 329-335. 
 
37. Parker B, Noakes M, Luscombe N, Clifton P. Effect of a high-protein, high–monounsaturated fat 
weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care 2002; 
25:425–430. 
 
38. Capstick F, Brooks BA, Burns CM, Zilkens RR, Steinbeck KS, Yue DK. Very low calorie diet 
(VLCD): A useful alternative in the treatment of the obese NIDDM patient. Diabetes Res Clin Pr 
1997; 36: 105-111. 
 
39. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss 
and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled 
study. Diabetes Obes Metab 2000; 2: 105-112. 
 
   
Page | 12 
 
40. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 
diabetes: normalisation of beta cell function in association with decreased pancreas and liver 
triacylglycerol. Diabetologia 2011: 54: 2506-2514. 
 
41. Anderson JW, Kendall CWC, Jenkins DJA. Importance of Weight Management in Type 2 
Diabetes: Review with Meta-analysis of Clinical Studies. J Am Coll Nutr 2003; 22: 331–339. 
 
42. Anderson JW, Konz EC, Frederich, RC, Wood CL. Long-term weight maintenance: a meta-
analysis of US studies. Am J Clin Nutr 2001; 74:579-84. 
 
43. Jakicic JM, Marcus BH, Lang W, Janney C. Effect of exercise on 24-month weight loss 
maintenance in overweight women. Arch Intern Med 2008; 168:1550-9. 
  
   
Page | 13 
 
 
 
Table 1 – Baseline characteristics of participants 
 
 
Variable All (710) T2DM (n=355) No-T2DM (n=355) 
Gender 
              M 
              F 
 
204 
506 
 
102 
253 
 
102 
253 
Age (years) 54.0 ± 9.1 54.0 ± 9.1 54.0 ± 9.1 
Height (m) 1.67 ± 0.1 1.67 ± 0.1 1.67 ± 0.1 
Weight (kg) 116.1 ± 25.1 115.0 ± 24.4 117.2 ± 25.8 
BMI (kg/m2) 41.6 ± 8.1 41.5 ± 8.6 41.7 ± 7.5 
BMI categories (kg/m2) 
 
        30.0 -34.9 
        35.0 – 39.9 
        40.0 – 44.9 
        45.0 – 49.9 
        50.0+ 
 
 
129 
222 
169 
109 
81 
 
 
68 
113 
81 
53 
40 
 
 
61 
109 
88 
56 
41 
Ethnicity 
            Black African 
            Black Caribbean 
            Black Other 
            Caucasian 
            Chinese 
            Indian 
            Pakistani 
            Undisclosed 
 
1 
3 
6 
619 
1 
14 
9 
57 
 
1 
3 
4 
305 
1 
12 
5 
24 
 
0 
0 
2 
314 
0 
2 
4 
33 
Measurements are reported as absolute numbers or as means ± standard deviation); BMI – body 
mass index 
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Table 2: Comparison of outcomes by gender.  
 T2DM Non-T2DM P 
between 
groups 
(males) 
P 
between 
groups 
(females) 
 Males Females P value Males Females P 
value 
  
Age (years) 54.2 ± 
9.3 
53.9 ± 
9.1 
0.787 54.2 ± 
9.3 
53.9 ± 
9.1 
0.776 0.989 0.996 
Height (m) 1.78 ± 
0.06 
1.62 ± 
0.07 
<0.001 1.77 ± 
0.06 
1.62 ± 
0.06 
<0.001 0.962 0.526 
Weight (kg) 126.8 ± 
25.9 
110.2 ± 
22.1 
<0.001 130.2 
± 25.1 
112.0 ± 
24.2 
<0.001 0.467 0.418 
BMI (kg/m2) 41.3 ± 
11.0 
41.6 ± 
7.5 
0.190 41.1 ± 
7.4 
42.0 ± 
7.6 
0.250 0.604 0.540 
Weight change 
at 12 weeks 
(kg) 
-20.3 ± 
9.3 
-17.4 ± 
6.2 
0.01 -23.7 ± 
8.6 
-18.4 ± 
5.6 
<0.001 0.020 0.173 
% weight 
change at 12 
weeks 
14.5 ± 
17.1 
15.9 ± 
4.9 
0.878 18.1 ± 
4.9 
16.7 ± 
4.2 
0.009 0.014 0.116 
Measurements are reported as means ± standard deviation; BMI – body mass index 
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Figure 1: Weekly weight change for patients with and without type 2 diabetes mellitus (T2DM) 
following a very low calorie diet for 12 weeks. * displays a significant difference in weight change 
between the two groups (P < 0.05). 
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